Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
Merck
Johnson and Johnson
Medtronic

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR SODIUM IODIDE I 123


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Sodium Iodide I 123

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00450814 ↗ Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2006-11-30 This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00450814 ↗ Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed Mayo Clinic Phase 1/Phase 2 2006-11-30 This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00638092 ↗ A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed National Institute for Health Research, United Kingdom Phase 4 2010-03-01 The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗ A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed University of Dundee Phase 4 2010-03-01 The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sodium Iodide I 123

Condition Name

Condition Name for Sodium Iodide I 123
Intervention Trials
Breast Cancer 4
Recurrent Plasma Cell Myeloma 2
Refractory Plasma Cell Myeloma 2
Ovarian Endometrioid Adenocarcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sodium Iodide I 123
Intervention Trials
Breast Neoplasms 4
Carcinoma 3
Neoplasms, Plasma Cell 3
Multiple Myeloma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sodium Iodide I 123

Trials by Country

Trials by Country for Sodium Iodide I 123
Location Trials
United States 13
United Kingdom 3
Korea, Republic of 2
Japan 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sodium Iodide I 123
Location Trials
Minnesota 6
Florida 2
Arizona 2
California 2
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sodium Iodide I 123

Clinical Trial Phase

Clinical Trial Phase for Sodium Iodide I 123
Clinical Trial Phase Trials
Phase 4 1
Phase 2 4
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sodium Iodide I 123
Clinical Trial Phase Trials
Recruiting 5
Completed 4
Terminated 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sodium Iodide I 123

Sponsor Name

Sponsor Name for Sodium Iodide I 123
Sponsor Trials
Mayo Clinic 6
National Cancer Institute (NCI) 5
Stanford University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sodium Iodide I 123
Sponsor Trials
Other 19
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.